These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19741185)

  • 21. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status.
    Xie M; Shan Z; Zhang Y; Chen S; Yang W; Bao W; Rong Y; Yu X; Hu FB; Liu L
    PLoS One; 2014; 9(10):e90286. PubMed ID: 25360605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of aspirin in patients with peripheral vascular disease: An updated systematic review and meta-analysis of randomized controlled trials.
    Mahmoud AN; Elgendy AY; Rambarat C; Mahtta D; Elgendy IY; Bavry AA
    PLoS One; 2017; 12(4):e0175283. PubMed ID: 28403216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force.
    Guirguis-Blake JM; Evans CV; Senger CA; O'Connor EA; Whitlock EP
    Ann Intern Med; 2016 Jun; 164(12):804-13. PubMed ID: 27064410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials.
    Sanmuganathan PS; Ghahramani P; Jackson PR; Wallis EJ; Ramsay LE
    Heart; 2001 Mar; 85(3):265-71. PubMed ID: 11179262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus.
    Pignone M; Williams CD
    Nat Rev Endocrinol; 2010 Nov; 6(11):619-28. PubMed ID: 20856266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of contemporary versus older studies of aspirin for primary prevention.
    Moriarty F; Ebell MH
    Fam Pract; 2020 Jul; 37(3):290-296. PubMed ID: 31751455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis.
    Zheng SL; Roddick AJ
    JAMA; 2019 Jan; 321(3):277-287. PubMed ID: 30667501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis.
    Zhou Y; Huang Y; Ji X; Wang X; Shen L; Wang Y
    J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 31822895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspirin for the prevention of cardiovascular morbidity.
    Sanchez-Ross M; Waller AH; Maher J; Klapholz M; Haider B; Kaluski E
    Minerva Med; 2010 Aug; 101(4):205-14. PubMed ID: 21030934
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis.
    Simpson SH; Gamble JM; Mereu L; Chambers T
    J Gen Intern Med; 2011 Nov; 26(11):1336-44. PubMed ID: 21647746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
    Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
    Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Liu S; Eckstein J; Lam A; Cheema AN
    Curr Vasc Pharmacol; 2023; 21(2):111-119. PubMed ID: 36718966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibrates for primary prevention of cardiovascular disease events.
    Jakob T; Nordmann AJ; Schandelmaier S; Ferreira-González I; Briel M
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009753. PubMed ID: 27849333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omega-6 fats for the primary and secondary prevention of cardiovascular disease.
    Hooper L; Al-Khudairy L; Abdelhamid AS; Rees K; Brainard JS; Brown TJ; Ajabnoor SM; O'Brien AT; Winstanley LE; Donaldson DH; Song F; Deane KH
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD011094. PubMed ID: 30488422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
    Wolff T; Miller T; Ko S
    Ann Intern Med; 2009 Mar; 150(6):405-10. PubMed ID: 19293073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.
    Joseph P; Roshandel G; Gao P; Pais P; Lonn E; Xavier D; Avezum A; Zhu J; Liu L; Sliwa K; Gamra H; Bangdiwala SI; Teo K; Diaz R; Dans A; Lopez-Jaramillo P; Prabhakaran D; Castellano JM; Fuster V; Rodgers A; Huffman MD; Bosch J; Dagenais GR; Malekzadeh R; Yusuf S;
    Lancet; 2021 Sep; 398(10306):1133-1146. PubMed ID: 34469765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin.
    Bartolucci AA; Tendera M; Howard G
    Am J Cardiol; 2011 Jun; 107(12):1796-801. PubMed ID: 21481826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.
    Berger JS; Krantz MJ; Kittelson JM; Hiatt WR
    JAMA; 2009 May; 301(18):1909-19. PubMed ID: 19436018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
    Valentine N; Van de Laar FA; van Driel ML
    Cochrane Database Syst Rev; 2012 Nov; 11():CD005449. PubMed ID: 23152231
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.